Neumora Therapeutics (NASDAQ:NMRA) Reaches New 52-Week Low at $8.98

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) reached a new 52-week low during trading on Thursday . The company traded as low as $8.98 and last traded at $9.09, with a volume of 138021 shares trading hands. The stock had previously closed at $9.59.

Wall Street Analyst Weigh In

NMRA has been the topic of several recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of Neumora Therapeutics in a report on Thursday, March 28th. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. Finally, JPMorgan Chase & Co. lifted their price target on Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.57.

Neumora Therapeutics Price Performance

The firm has a 50-day moving average of $14.64 and a two-hundred day moving average of $14.07.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.05. As a group, analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently made changes to their positions in NMRA. FMR LLC acquired a new position in shares of Neumora Therapeutics in the 3rd quarter worth approximately $79,360,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST acquired a new position in Neumora Therapeutics during the third quarter worth $46,692,000. Avidity Partners Management LP purchased a new position in shares of Neumora Therapeutics during the third quarter worth $25,398,000. Johnson & Johnson acquired a new stake in shares of Neumora Therapeutics in the third quarter valued at $12,870,000. Finally, Addis & Hill Inc purchased a new stake in shares of Neumora Therapeutics in the 1st quarter valued at $4,187,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.